View Item 

Show simple item record

Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis
dc.contributor.authorClain, J. M.
dc.contributor.authorHummel, A. M.
dc.contributor.authorStone, J. H.
dc.contributor.authorFervenza, F. C.
dc.contributor.authorHoffman, G. S.
dc.contributor.authorKallenberg, C. G. M.
dc.contributor.authorLangford, C. A.
dc.contributor.authorMcCune, W. J.
dc.contributor.authorMerkel, P. A.
dc.contributor.authorMonach, P. A.
dc.contributor.authorSeo, P.
dc.contributor.authorSpiera, R. F.
dc.contributor.authorSt Clair, E. W.
dc.contributor.authorYtterberg, S. R.
dc.contributor.authorSpecks, U.
dc.date.accessioned2017-04-14T15:12:05Z
dc.date.available2018-05-15T21:02:51Zen
dc.date.issued2017-04
dc.identifier.citationClain, J. M.; Hummel, A. M.; Stone, J. H.; Fervenza, F. C.; Hoffman, G. S.; Kallenberg, C. G. M.; Langford, C. A.; McCune, W. J.; Merkel, P. A.; Monach, P. A.; Seo, P.; Spiera, R. F.; St Clair, E. W.; Ytterberg, S. R.; Specks, U. (2017). "Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis." Clinical & Experimental Immunology 188(1): 174-181.
dc.identifier.issn0009-9104
dc.identifier.issn1365-2249
dc.identifier.urihttps://hdl.handle.net/2027.42/136522
dc.publisherWiley Periodicals, Inc.
dc.subject.otheranti‐neutrophil cytoplasmic antibodies
dc.subject.othergranulomatosis with polyangiitis
dc.subject.otheralveolar haemorrhage
dc.subject.otherANCA‐associated vasculitis
dc.subject.othermicroscopic polyangiitis
dc.subject.otherimmunoglobulin M
dc.titleImmunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMicrobiology and Immunology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136522/1/cei12925.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136522/2/cei12925_am.pdf
dc.identifier.doi10.1111/cei.12925
dc.identifier.sourceClinical & Experimental Immunology
dc.identifier.citedreferenceYuki N, Taki T, Inagaki F et al. A bacterium lipopolysaccharide that elicits Guillain–Barré syndrome has a GM1 ganglioside‐like structure. J Exp Med 1993; 178: 1771 – 5.
dc.identifier.citedreferenceNassberger L, Sjoholm AG, Bygren P, Thysell H, Hojer‐Madsen M, Rasmussen N. Circulating anti‐neutrophil cytoplasm antibodies in patients with rapidly progressive glomerulonephritis and extracapillary proliferation. J Intern Med 1989; 225: 191 – 6.
dc.identifier.citedreferenceEsnault VL, Ronda N, Jayne DR, Lockwood CM. Association of ANCA isotype and affinity with disease expression. J Autoimmun 1993; 6: 197 – 205.
dc.identifier.citedreferenceKelley JM, Monach PA, Ji C et al. IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proc Natl Acad Sci USA 2011; 108: 20736 – 41.
dc.identifier.citedreferenceEsnault VL, Soleimani B, Keogan MT, Brownlee AA, Jayne DR, Lockwood CM. Association of IgM with IgG ANCA in patients presenting with pulmonary hemorrhage. Kidney Int 1992; 41: 1304 – 10.
dc.identifier.citedreferenceJennings JG, Chang L, Savige JA. Anti‐proteinase 3 antibodies, their characterization and disease associations. Clin Exp Immunol 1994; 95: 251 – 6.]
dc.identifier.citedreferenceNassberger L, Geborek P. IgM–ANCA in a patient with systemic vasculitis without pulmonary involvement. Clin Nephrol 1990; 34: 280.
dc.identifier.citedreferenceWGET Research Group. Design of the Wegener’s Granulomatosis Etanercept Trial (WGET). Control Clin Trials 2002; 23: 450 – 68.
dc.identifier.citedreferenceEtanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 2005; 352: 351 – 61.
dc.identifier.citedreferenceStone JH, Hoffman GS, Merkel PA et al. A disease‐specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001; 44: 912 – 20.
dc.identifier.citedreferenceSpecks U, Merkel PA, Hoffman GS et al. Design of the rituximab in ANCA‐Associated Vasculitis (RAVE) Trial. Open Arthritis J 2011; 4: 1 – 18.
dc.identifier.citedreferenceStone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA‐associated vasculitis. N Engl J Med 2010; 363: 221 – 32.
dc.identifier.citedreferenceFinkielman JD, Lee AS, Hummel AM et al. ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med 2007; 120: 643 e9 – 14.
dc.identifier.citedreferenceCapizzi SA, Viss MA, Hummel AM, Fass DN, Specks U. Effects of carboxy‐terminal modifications of proteinase 3 (PR3) on the recognition by PR3–ANCA. Kidney Int 2003; 63: 756 – 60.
dc.identifier.citedreferenceSun J, Fass DN, Hudson JA et al. Capture‐ELISA based on recombinant PR3 is sensitive for PR3–ANCA testing and allows detection of PR3 and PR3–ANCA/PR3 immunecomplexes. J Immunol Methods 1998; 211: 111 – 23.
dc.identifier.citedreferenceSilva F, Hummel AM, Jenne DE, Specks U. Discrimination and variable impact of ANCA binding to different surface epitopes on proteinase 3, the Wegener’s autoantigen. J Autoimmun 2010; 35: 299 – 308.
dc.identifier.citedreferenceHinkofer LC, Seidel SAI, Korkmaz B et al. A monoclonal antibody (MCPR3‐7) interfering with the activity of proteinase 3 by an allosteric mechanism. J Biol Chem 2013; 288: 26635 – 48.
dc.identifier.citedreferenceRoot‐Bernstein R, Fairweather D. Complexities in the relationship between infection and autoimmunity. Curr Allergy Asthma Rep 2014; 14: 407.
dc.identifier.citedreferenceKusunoki S, Shiina M, Kanazawa I. Anti‐Gal‐C antibodies in GBS subsequent to mycoplasma infection: evidence of molecular mimicry. Neurology 2001; 57: 736 – 8.
dc.identifier.citedreferenceYuki N, Hartung HP. Guillain–Barré syndrome. N Engl J Med 2012; 366: 2294 – 304.
dc.identifier.citedreferenceRaynauld JP, Bloch DA, Fries JF. Seasonal variation in the onset of Wegener’s granulomatosis, polyarteritis nodosa and giant cell arteritis. J Rheumatol 1993; 20: 1524 – 6.
dc.identifier.citedreferenceCarruthers DM, Watts RA, Symmons DP, Scott DG. Wegener’s granulomatosis – increased incidence or increased recognition? Br J Rheumatol 1996; 35: 142 – 5.
dc.identifier.citedreferenceTidman M, Olander R, Svalander C, Danielsson D. Patients hospitalized because of small vessel vasculitides with renal involvement in the period 1975–95: organ involvement, anti‐neutrophil cytoplasmic antibodies patterns, seasonal attack rates and fluctuation of annual frequencies. J Intern Med 1998; 244: 133 – 41.
dc.identifier.citedreferenceDuna GF, Cotch MF, Galperin C, Hoffman DB, Hoffman GS. Wegener’s granulomatosis: role of environmental exposures. Clin Exp Rheumatol 1998; 16: 669 – 74.
dc.identifier.citedreferenceKoldingsnes W, Nossent H. Epidemiology of Wegener’s granulomatosis in northern Norway. Arthritis Rheum 2000; 43: 2481 – 7.
dc.identifier.citedreferenceFalk RJ, Hogan S, Carey TS, Jennette JC. Clinical course of anti‐neutrophil cytoplasmic autoantibody‐associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med 1990; 113: 656 – 63.
dc.identifier.citedreferenceChoi HK, Lamprecht P, Niles JL, Gross WL, Merkel PA. Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti‐proteinase 3 antibodies. Arthritis Rheum 2000; 43: 226 – 31.
dc.identifier.citedreferenceMahr A, Batteux F, Tubiana S et al. Brief report: prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis. Arthritis Rheumatol 2014; 66: 1672 – 7.
dc.identifier.citedreferenceYing CM, Yao DT, Ding HH, Yang CD. Infective endocarditis with antineutrophil cytoplasmic antibody: report of 13 cases and literature review. PLOS ONE 2014; 9: e89777.
dc.identifier.citedreferenceKallenberg CG, Tadema H. Vasculitis and infections: contribution to the issue of autoimmunity reviews devoted to ‘autoimmunity and infection ’. Autoimmun Rev 2008; 8: 29 – 32.
dc.identifier.citedreferenceBoes M. Role of natural and immune IgM antibodies in immune responses. Mol Immunol 2000; 37: 1141 – 9.
dc.identifier.citedreferenceRacine R, Winslow GM. IgM in microbial infections: taken for granted? Immunol Lett 2009; 125: 79 – 85.
dc.identifier.citedreferenceJacobs E. Serological diagnosis of Mycoplasma pneumoniae infections: a critical review of current procedures. Clin Infect Dis 1993; 17 Suppl 1: S79 – 82.
dc.identifier.citedreferenceSwiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood 2013; 122: 1114 – 21.
dc.identifier.citedreferenceJennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1 – 11.
dc.identifier.citedreferenceSeo P, Stone JH. The antineutrophil cytoplasmic antibody‐associated vasculitides. Am J Med 2004; 117: 39 – 50.
dc.identifier.citedreferenceStegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120: 12 – 7.
dc.identifier.citedreferenceFinkielman JD, Merkel PA, Schroeder D et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007; 147: 611 – 9.
dc.identifier.citedreferenceFussner LA, Hummel AM, Schroeder DR, et al. Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheumatol 2016; 68: 1700 – 10.
dc.identifier.citedreferenceJayne DR, Jones SJ, Severn A, Shaunak S, Murphy J, Lockwood CM. Severe pulmonary hemorrhage and systemic vasculitis in association with circulating anti‐neutrophil cytoplasm antibodies of IgM class only. Clin Nephrol 1989; 32: 101 – 6.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cei12925.pdf
Size:
310.2KB
Format:
PDF
View/Open
Name:
cei12925_am.pdf
Size:
3.717MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.